CTG Labs – NCBI
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Related Articles
Best Practices and Practical Nuances in the Treatment of Gastric Cancer in High-Risk Global Areas
Gastric cancer is an aggressive disease that is very frequent in Latin America. The reasons for this increased incidence is not clear. Associated with the…
Program Guide – ASCO Meeting Program Guide
Miguel Gonzalez Velez Mayo Clinic Arizona, Phoenix, AZ Miguel Gonzalez Velez, Narjust Duma, Daniel Cabrera, Ariela L. Marshall, Deanna J. Attai, Merry Jennifer Markham, Rafael…
Home | United States | PROMISE Study: Researching Multiple Myeloma
See if you qualify for a study screening to detect early indicators of blood cancer known as multiple myeloma. Visit The Promise Study now, part…
Familial Multiple Myeloma: Insights From Epidemiology and Underlying Germline Genetic Predisposition to the Clinic
Familial multiple myeloma (MM) is a relatively rare entity. Data on epidemiology, underlying germline genetic predisposition, and clinical features of familial MM continue to expand,…
Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19
Patients treated recently for a B-lymphoid malignancy are shown to have particularly high risks of severe COVID-19 compared to multiple control cohorts of patients with…
Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19: An International, Randomised, Open-Label Trial
Background: COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19. This study investigated the safety and efficacy of early, very high-titre CCP
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients
This systematic review and meta-analysis assesses reports of clinical experiences of patients with COVID-19 and immunosuppression who were treated with specific neutralizing antibodies via COVID-19…
Time-Related Biases in Nonrandomized COVID-19–Era Studies Using Real-world Data
The urgent response to the COVID-19 pandemic has highlighted the importance of diverse, real-world data sources, such as electronic health records, insurance claims, and patient…
Survival in Patients With Hematologic Cancers and COVID-19
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19.